Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process
In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States Food and Drug […]
Other Corporate Information
Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018
Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free
Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007
The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult male) is based
Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®
Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for
Isofol reports successful outcome from the scientific advice with the EMA
Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate
Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US
Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO), the worlds leading oncology
Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed
Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a successful regulatory meeting with the
Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer
Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from patients treated during 16 weeks
Isofol to present at the 10th Annual Biotech Showcase Conference
Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief Commercial Officer Sven
Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018
Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment has been accepted for presentation